Use Of Melphalan (M)/Dexamethasone (D)/Bortezomib In Al Amyloidosis
JOURNAL OF CLINICAL ONCOLOGY(2010)
Abstract
8024^ Background: AL amyloidosis is a monoclonal plasma cell disorder with progressive organ dysfunction and short survival. Standard non-transplant AL therapy is melphalan (M) + dexamethasone (D). As adding bortezomib (Bz) to M+ Prednisone improved outcomes in myeloma, we sought to determine if adding Bz to MD improves outcomes in AL. Methods: Eligibility: ECOG PS ≤ 3, Cr ≤ 5 mg/dL, T.Bili ≤ 2.5 × IULN, ALT/AST ≤ 3 × IULN, ANC ≥ 1.0 K/mm3, PLT ≥ 80 K/mm3, peripheral neuropathy (PN) ≤ Gr 2 (≤ 1 if painful), no lower limit for LVEF. Design: Two-stage phase II study. Stage I: 16 pts with biopsy-proven AL, light chain deposition disease (LCDD) or smoldering myeloma with amyloid (SMM). 1o endpoint: complete hematologic responses (cHR). If ≥5 cHRs observed, then 2nd stage with 17 more pts, giving 90% power to detect a true cHR rate of 50%. 2o endpoints: overall HR, organ response (OrR), and survival. Therapy: M (9 mg/m2 PO d 1-4; 6 mg/m2 if Cr > 2.5 mg/dL), Bz (1.3 mg/m2 IV d 1, 8, 15, 22; 1.0 mg/m2 if baselin...
MoreTranslated text
Key words
melphalan amyloidosis,m/dexamethasone
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined